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a b s t r a c t
Human papillomavirus type 16 (HPV-16) associated oropharyngeal cancers are on a signiﬁcant increase
and better therapeutic strategies are needed. The HPV-16 oncogenes E6 and E7 are expressed in HPV-
associated cancers and are able to transform human tonsillar epithelial cells (HTECs). We used cell-
Systematic Evolution of Ligands by Exponential Enrichment (SELEX) to select for RNA aptamers that
entered into HPV-16 E6/E7-HTECs. After 12 rounds of cell-SELEX, a pool of aptamers was obtained that
had signiﬁcantly greater internalization capacity (5-fold) into E6/E7-HTECs as compared to primary
HTECs or ﬁbroblasts. Analysis of individual aptamers from the pool indicated variable internalization into
E6/E7-HTECs (1–8-fold as compared to a negative control). Most of the individual aptamers internalized
into E6/E7 and primary HTECs with similar efﬁciency, while one aptamer exhibited 3-fold better
internalization into E6/E7-HTECs. Aptamers that internalize into cells may be useful for delivering
therapeutic agents to HPV-16 associated malignancies.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Ninety-nine percent of cervical cancer, more than 50% of anal,
vaginal, vulvar, and penile cancers, and a subset of head and neck
cancers are caused by high-risk human papillomaviruses (HPVs)
(Moody and Laimins, 2010). While there are several types of HPVs
associated with cancer, HPV-16 accounts for the majority of
cervical cancers and nearly all HPV-associated head and neck
cancers (HNCs). Currently available vaccines can do nothing for the
millions of people that are already infected with HPV and
compliancy rates for vaccination have fallen well short of expecta-
tions (Dillard and Spear, 2010). HPV-associated HNCs, particularly
oropharyngeal (tonsillar) cancers, are on the rise in both men and
women (Chaturvedi et al., 2011; Marur et al., 2010). Few new
treatment strategies for HPV positive or negative HNCs have emerged
in recent decades and there is a pressing need for novel therapies.
HPV-positive HNCs are considered to have a better prognosis
than HPV-negative HNCs, in general, but a signiﬁcant subset do not
respond to therapy and metastasize (Huang et al., 2013). Genetic and
microarray expression studies of HPV positive and HPV negative
HNCs indicate that they are clearly two separate entities, with HPV-
positive HNCs having many fewer mutations than HPV-negative
HNCs, which goes along with their viral etiology (Agrawal et al.,
2011; Pyeon et al., 2007; Stransky et al., 2011). Two viral-speciﬁc
oncogenes called E6 and E7 are expressed in HPV-associated
cancers (Klingelhutz and Roman, 2012). We and others have
demonstrated that HPV-16 E6 and E7 together can immortalize
human and mouse head and neck epithelial cells (Al Moustafa et al.,
2004; Hoover et al., 2007; Spanos et al., 2008). The E6 and E7
proteins inactivate the p53 and pRb tumor suppressor proteins,
respectively, and also activate telomerase (Dyson et al., 1989;
Klingelhutz et al., 1996; Scheffner et al., 1990). HPV-16 E6 and E7
interact with numerous cellular proteins and alter a vast array of
pathways involved in transformation (Klingelhutz and Roman,
2012). Expression of E6 and E7 are essential for transformation
and continuous proliferation. Inhibition of expression or knock-
down by siRNA causes HPV transformed cells to rapidly senesce
and/or apoptose (Butz et al., 2003; Jiang and Milner, 2002;
Tang et al., 2006).
RNA aptamers are synthetic RNAs that can speciﬁcally bind to
targets of interest (Thiel and Giangrande, 2009). They are derived
from combinatorial sequence libraries by a process called SELEX
(Systematic Evolution of Ligands by EXponential Enrichment)
(Blank et al., 2001). This methodology has been modiﬁed in such
a way that it can be cell based (cell-SELEX) (Cerchia et al., 2009b;
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Shamah et al., 2008). Multiple rounds of selection and ampliﬁca-
tion allow enrichment of RNA aptamers that can bind selectively to
certain cell types and internalize. Contrary to selection conducted
by in vitro expressed proteins, cell-SELEX enables the isolation of
RNA aptamers that bind to receptors in their native state and
selects speciﬁcally for those that can be internalized into cells. The
aptamers are synthesized with 2′-ﬂuoropyrimidines to make them
resistant to nuclease-mediated degradation (Cerchia et al., 2009b).
Aptamers can be easily synthesized in large quantities and the
smaller size, as compared to antibodies, facilitates delivery by
allowing better tissue penetration. Aptamers have been utilized to
target different proteins including transcription factors and cell
surface receptors (Cerchia and de Franciscis, 2010; Giangrande
et al., 2007; Mi et al., 2008; Shangguan et al., 2008, 2006; Wan
et al., 2010). Conjugation of ﬂuorescent or radioactive tags to
protein-speciﬁc aptamers has been shown to be a means to
tag/detect cancer cells that express that protein (Cerchia and de
Franciscis, 2010). In addition, immobilized protein-speciﬁc apta-
mers (e.g. aptamers against EGFR) have been utilized to speciﬁ-
cally capture cancer cells from the blood, a method that could be
used as a possible means for early cancer detection (Pu et al.,
2010). Selecting aptamers that speciﬁcally bind to transformed
cells also offers the possibility of identifying proteins that are
upregulated in cancer cells (Shangguan et al., 2007a). A number of
publications have demonstrated that protein or cell-speciﬁc apta-
mers can be utilized to inhibit protein function (McNamara et al.,
2008; Mi et al., 2008). In addition to direct interaction of aptamers
with cellular proteins, aptamers can be used to deliver siRNA into
cells. For example, aptamer-siRNA chimeras have been developed
that mediate binding to PSMA, a cell-surface receptor expressed
on prostate cancer cells, followed by internalization and speciﬁc
delivery of growth inhibiting siRNA to PSMA expressing prostate
cells in vitro and in vivo (Dassie et al., 2009; Lupold et al., 2002;
McNamara et al., 2006). A similar aptamer-siRNA methodology has
been utilized to target the HIV gp120 protein to deliver siRNA
to inhibit tat/rev and suppress HIV replication (Zhou et al., 2008).
It has also been proposed that cell-speciﬁc aptamers could be used
in conjunction with nanoparticles to increase nanoparticle speci-
ﬁcity and internalization (Cerchia and de Franciscis, 2010; Dua
et al., 2011; Yang et al., 2012).
In this study, we have utilized cell-SELEX to identify RNA
aptamers that efﬁciently internalize into HPV-16 E6/E7 trans-
formed human tonsillar epithelial cells. These aptamers may
provide a mechanism to deliver therapeutic siRNA or other
cytotoxic agents to HPV-16 associated cancers.
Results
Aptamer selection strategy
For these studies, we used HPV-16 E6/E7 transformed HTECs
that were generated as previously described (Spanos et al., 2008).
The HPV-16 E6/E7 transformed HTECs represent an early stage of
HPV-associated transformation and should exhibit alterations that
are speciﬁc for HPV transformation and not individualized altera-
tions that have been selected for in speciﬁc cancer cell lines.
Previous microarray expression studies from our lab and others
have demonstrated that HPV-16 E6/E7 expression causes changes
in expression of a large number of cellular genes, including many
that code for cell-surface proteins (and hence would be good
targets for aptamers) (Duffy et al., 2003; Pyeon et al., 2007; Wan
et al., 2008). To identify aptamers that speciﬁcally bind to and
internalize into HPV-16 transformed head and neck epithelial
cells, we utilized cell-SELEX with a complex RNA aptamer library
with a 30 nucleotide variable sequence and an estimated starting
complexity of greater than 1018. The RNA aptamers were synthe-
sized using 2′-ﬂuoropyrimidine to provide stability and inhibit
degradation by RNAses. Each round of cell-SELEX involved a pre-
clearing step with primary HTECs for removal of aptamers that
bind to non-transformed cells (negative selection) and a positive
selection step against the target using HPV-16 E6/E7-HTECs (Fig. 1).
With each round, we progressively increased the selective pres-
sure by decreasing concentration and increasing incubation times
Fig. 1. Strategy for cell-SELEX (Systematic Evolution of Ligands by Exponential Enrichment). A pool of oligonucleotides with a 30 base random internal sequence were
converted to double-stranded DNA and then into 2′ ﬂuoropyrimidine modiﬁed RNA aptamers using a T7 polymerase. The pool of aptamers was ﬁrst pre-cleared using
primary human tonsillar epithelial cells (HTECs). Aptamers that did not bind and internalize were incubated with HPV-16 E6/E7 transformed HTECs and allowed to
internalize. The cells were stringently washed with high salt, followed by lysis and puriﬁcation of the RNA. After RNAse treatment (to remove the cellular RNA but not the
resistant aptamers), the RNA was reverse transcribed and PCR-ampliﬁed. The ampliﬁed DNA was then transcribed into new aptamers and used in subsequent rounds of
selection.
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in the primary HTECs and shortening binding/internalization time
in the target HPV-16 E6/E7 transformed cells (Table 1).
A total of 12 rounds of negative and positive selection were
performed. With each round, cell extracts were prepared and
RNA isolated. After removal of cellular RNA, extracted aptamers
were precipitated, reverse transcribed, and PCR ampliﬁed with an
added T7 promoter. New 2′-ﬂuoropyrimidine modiﬁed RNA was
then generated for the next round of selection.
Convergence of aptamer sequences that differentially internalize
into E6/E7-HTECs
Aptamer pools from selected rounds (early round 2 and late
round 12) were then tested for their differential ability to inter-
nalize into E6/E7-HTECs as compared to primary HTECs. The pool
of aptamers in round 12 were much more efﬁcient at internalizing
into E6/E7-HTECs and less efﬁcient at internalizing into primary
HTECs than the earlier round aptamers (Fig. 2A). Thus, we were
able to enrich for aptamers that bind/internalize better into 16E6/
E7 transformed cells as compared to primary normal cells. The
difference was approximately 5-fold (compare round 12 to round
2). In addition, the aptamer pools from the later rounds were poor
at internalizing into human ﬁbroblasts, indicating cell-type speci-
ﬁcity (Fig. 2A).
The above studies demonstrate that the cell-SELEX methodol-
ogy resulted in the selection of a pool of aptamers that could
differentially bind and internalize into E6/E7-HTECs. It would
therefore be expected that the later aptamer rounds would be
enriched for aptamers of certain sequences or structures that
provided for better and more speciﬁc internalization into 16E6/
E7 transformed cells. To identify individual aptamers, we per-
formed 454 sequencing on reverse transcribed aptamer pools from
the different rounds. Comparison of sequences that were obtained
allowed a determination of whether enrichment had occurred.
Percent enrichment was calculated as 1(Unique Sequences/Total
Sequences)100 where fewer unique sequences represents less
complexity and more enrichment (Thiel et al., 2012b, 2011). We
found that the percent enrichment did not increase substantially
after 5 rounds of selection (data not shown) but increased with
subsequent rounds (rounds 6–12) of SELEX, indicating that apta-
mer pool complexity decreased with increasing selection (Fig. 2B
and Table 2). Still, a large number of different sequences were
present in the population. We chose to follow up on six aptamers
that were the most common and that showed increases in number
with increasing rounds of selection. If families of aptamers with
clearly related sequences were present, we chose the most highly
represented aptamer for follow-up studies. Theoretical structures
of least energy were generated by M-fold for the six aptamers.
These structures along with the sequence of the variable region
for each aptamer are shown in Fig. 3 and Table 3. While some of
the aptamers have similar theoretical structures, there is some
Table 1
Parameters of cell-SELEX selection.
Rd1a Rd2 Rd3 Rd4 Rd5 Rd6 Rd7 Rd8 Rd9 Rd10 Rd11 Rd12
Concentration
(beginning) (nM)
2 2 2 1 1 1 0.5 0.5 0.5 0.5 0.5 0.5
Pre-clearing time on
HTECs and
number of
sequential plates
20 min
2 plates
20 min
1 plate
40 min 1
plate
40 min 
3 plates
15 min
3 plates
15 min
3 plates
15 min
3 plates
20 min
4 plates
20 min
4 plates
20 min
4 plates
20 min
4 plates
20 min 
4 plates
Internalization time on
16E6/E7 HTECs (min)
75 75 75 75 75 75 30 30 30 20 20 20
a Rd¼Round of cell-SELEX.
Fig. 2. Internalization of selected RNA aptamer pools and convergence of aptamer
sequences. (A) Aptamer pools from rounds 2 and 12 were tested on primary HTECs
(HTEC), 16E6/E7 HTECs (E6/E7 HTEC), and primary ﬁbroblasts. The pools were
incubated with the cells to allow for binding and internalization, followed by
stringent washing, isolation of RNA, and quantiﬁcation as described in the section
“Materials and methods”. The quantity is displayed as the ratio of the aptamers
(Sel2) over an internal spiked control (added after Trizol extraction) called Sel1 all
normalized to GAPDH (measured from a separated non-RNAse treated fraction) and
made relative to primary HTECs (*po0.05, Student's t-test). (B) An analysis of
sequences from 454 sequencing was performed as described in the section
“Materials and methods” to determine library complexity with increasing rounds
of selection. A higher percent indicates enrichment and less complexity.
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diversity, suggesting that the selected aptamers may have different
mechanisms of binding and/or entry into the E6/E7 transformed
cells. It should be noted that these structures are theoretical; other
folding patterns are possible.
Internalization of individual aptamers into E6/E6 transformed cells
To assess internalization, the individual aptamers were incu-
bated with E6/E7-HTECs followed by stringent washing, RNA
extraction, and RT-qPCR. Although variability in internalization
was observed, most of the individual aptamers, except C4, inter-
nalized better into E6/E7-HTECs as compared to internalization by
a negative control aptamer (Fig. 4A). Two of the aptamers, B8 and
C5, internalized approximately 5 and 8-fold, respectively, better
than a negative control aptamer. The heterogeneity of internaliza-
tion between the individual aptamers indicates some measure of
speciﬁcity. Unexpectedly, most of the tested aptamers exhibited
similar internalization into E6/E7-HTECs and primary HTECs, with
2-fold or less difference (Fig. 4B). One aptamer, C5, which
internalized with the highest efﬁciency, also differentially inter-
nalized 3.0 fold better into E6/E7-HTECs as compared to primary
HTECs. This aptamer was chosen for further studies.
As another measure of internalization, the C5 aptamer was
ﬂuorescently labeled with Cy3. We then assessed internalization
by incubating with E6/E7-HTECs or primary HTECs, followed by
stringent washes, trypsinization, and FACS analysis. In this assay,
the labeled C5 aptamer was found to internalize better into E6/E7-
HTECs better than it did into primary HTECs (9% shift compared
to 1%) (Fig. 5A). Using Hoechst stain, we were also able to
distinguish between live and dead cells, and we found that most
internalization was in live cells with minimal background in dead
cells. To determine if the aptamer internalized into other HPV-16
transformed cells, we incubated the labeled C5 aptamer with
primary cervical and 16E6/E7 immortalized human cervical
epithelial (HCE) cells. The aptamer internalized into primary HCE
cells, but it was better at internalizing into 16E6/E7-HCE cells (22%
shift as compared to 9%) (Fig. 5B), suggesting that E6/E7 expres-
sing cells were more efﬁcient at binding and internalizing the C5
aptamer.
To assess cellular localization after internalization, we incu-
bated E6/E7-HTECs with labeled C5 aptamer and examined the
cells using ﬂuorescence microscopy. The aptamer localized to
punctate spots in the cytoplasm (Fig. 6). Internalization was found
to be dependent on incubation at 37 1C, indicating a mechanism of
active uptake (Fig. 6).
Discussion
In this study, we utilized cell-SELEX to identify RNA aptamers
that can internalize into HPV-16 E6/E7 transformed tonsillar
epithelial cells. Our selection strategy resulted in a pool of
aptamers that were better at internalizing into E6/E7-HTECs than
primary HTECs or ﬁbroblasts. The individual aptamers exhibited
different levels of internalization ability and one aptamer, C5,
exhibited increased 3-fold increased internalization for E6/E7-
HTECs as compared to primary HTECs.
Cell-SELEX has provided a means for identifying aptamers
that differentially bind and internalize better into cancer cells as
compared to non-transformed or non-metastasizing cells (Cerchia
et al., 2009a; Chen et al., 2008; Mi et al., 2010; Sefah et al., 2010;
Shangguan et al., 2006, 2007b; Tang et al., 2007; Thiel et al.,
2012a). To our knowledge, aptamers that speciﬁcally internalize
into HPV transformed cells have not been reported. However, in a
recent study, cell-SELEX was used to identify aptamers that bound
and internalized into revertants of Hela (HPV-18 positive) cells
that were no longer tumorigenic (Graham and Zarbl, 2012). In
other words, those aptamers that were identiﬁed were better at
internalizing into non-tumorigenic cells than tumorigenic cells. In
our studies, we were interested in isolating aptamers that inter-
nalized speciﬁcally into HPV transformed tonsillar epithelial cells.
To do this, we used a pre-clearing step in which we ﬁrst incubated
the aptamer library with primary normal HTECs. This pre-clearing
should have removed a population of aptamers that can bind and
enter into primary cells. The aptamers that did not internalize
were then used for internalization into E6/E7-HTECs to select for
those that were better at internalizing into HPV-16 transformed
cells. These latter aptamers were then isolated and re-ampliﬁed
for subsequent rounds of pre-clearing and selection. After 12
rounds, the pool of aptamers that remained was better able to
internalize into E6/E7-HTECs as compared to primary HTECs,
indicating that selection and convergence had been successful.
However, while most of the individual aptamers that we selected
from round 12 internalized into E6/E7-HTECs, our results would
suggest that most of them did not differentially internalize to any
large degree. In other words, they bound and internalized into
both HTECs and E6/E7-HTECs with similar efﬁciency. The reason
for this result is not entirely clear. One possibility is that the cell-
SELEX strategy we utilized was not stringent enough in the pre-
clearing step and only a subpopulation of aptamers in the pool can
differentially internalize. If that is the case, we would simply need
to increase the number of rounds of cell-SELEX and/or test more
individual aptamers for differential internalization. In addition, E6/
E7-HTECs and primary HTECs are likely to share many of the same
aptamer targets since they are from the same origin and it may be
difﬁcult to ﬁnd aptamers that can differentiate between the two
cell types. Using HPV transformed cells that represent a more
malignant stage in cell-SELEX might have resulted in more cell-
speciﬁc aptamers. Another possibility is that speciﬁcity and inter-
nalization could arise through interactions that involve combina-
tions of aptamers. A mechanism such as this is certainly not
unprecedented in the virus world, in which receptors and co-
receptors are needed for efﬁciency and speciﬁcity. This hypothesis
could be tested by using various combinations of different apta-
mers to determine if speciﬁcity or efﬁciency is increased. While
the individual aptamers that we identiﬁed did not have high
speciﬁcity, characterization of aptamer targets through mass
spectrometry techniques (Li et al., 2009; Mallikaratchy et al.,
2007; Mi et al., 2010) or other methods might allow the develop-
ment of more stringent strategies to increase speciﬁcity (e.g.
through further selection against a known protein target). Deter-
mination of the mechanism of uptake could also lead to better
insight into what is necessary for internalization and speciﬁcity
which, in turn, could lead to identiﬁcation of aptamers with higher
speciﬁcity.
The single aptamer, C5, was found to consistently internalize
better into 16E6/E7 cells as compared to primary cells. As mentioned,
the level of differential internalizationwas not remarkable (3-fold)
Table 2
Common aptamers found by 454 sequencing that increase in later rounds of
cell-SELEX.
Aptamer Rd6 Rd7 Rd8 Rd9 Rd10 Rd11 Rd12
B2 3a 88 382 555 823 950 567
B8 1 79 119 232 259 486 534
C2 1 51 77 201 344 946 967
C3 1 3 11 36 249 1028 927
C4 1 80 139 203 266 340 407
C5 1 1 51 85 193 397 437
a Represents the number of times that an individual aptamer was identiﬁed by
deep sequencing of the pool of aptamers from each round of cell-SELEX.
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and depended on the type of assay that was used. For RT-qPCR, the
difference was approximately 3-fold, whereas using ﬂuorescently
labeled aptamer, the difference was represented by a small shift in
ﬂuorescence intensity in the pool of cells. The reasons for these
differences in results are not entirely clear, but it has been demon-
strated that assays to measure aptamer internalization often yield
variable results and can depend upon the speciﬁc aptamer that is
being studied (Hernandez et al., 2013). Modiﬁcations to the
aptamer (e.g. through the ﬂuorescent tag) could have also
resulted in a change in structure and the ability to bind and
internalize. Further studies using different aptamer concentra-
tions, different incubation times, and different tagging methods
will be essential to determine what methods are best for asses-
sing internalization capacity. Whether C5 is an aptamer that
would be useful for cell-speciﬁc targeting of HPV-16 transformed
cells remains to be determined. Higher speciﬁcity might be
Fig. 3. Theoretical structures of selected aptamers. The structure with the minimum free energy was determined for aptamers that increased in number with more selection.
Sequences of the variable region of the aptamers are shown. Theoretical structures of RNA were evaluated using M-fold. DeltaG (ΔG) values are noted below the structure.
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necessary, particularly if an aptamer (or its target) is to be used as
a biomarker.
As mentioned, previous studies have shown that RNA aptamers
can be used for delivery of siRNA to cells, both in vitro and in vivo.
One possibility would be to generate aptamer-siRNA chimeras
that target HPV E6 and/or E7 expression, as has been done with
PSMA-speciﬁc chimeras for prostate cancer (Dassie et al., 2009;
McNamara et al., 2006). These chimeras would enter cells and
speciﬁcally target viral genes. Such a strategy may allow more
efﬁcient and speciﬁc delivery of siRNAs to HPV-associated
Table 3
Aptamer sequences.
Aptamer 5′ Constant Variable sequence 3′ Constant
B2 GGGAGGACGAUGCGG TCCTAATCGTCGATTCCTCTGTATCCGCCC CAGACGACUCGCCCGA
B8 GGGAGGACGAUGCGG CGATCGATTGAACTGGGATATATGCCGCCC CAGACGACUCGCCCGA
C2 GGGAGGACGAUGCGG TATGTGTCTGGGGTTAAATCGTGGGCTCCC CAGACGACUCGCCCGA
C3 GGGAGGACGAUGCGG CTGACGAACTCCTCGTGATGAGGCCTTCTG CAGACGACUCGCCCGA
C4 GGGAGGACGAUGCGG ATAGGCGATATGCATCGTCACGTCGTGCCC CAGACGACUCGCCCGA
C5 GGGAGGACGAUGCGG AAGCATCAAGGGTGATCGTTTGACCCTCCC CAGACGACUCGCCCGA
Neg. Con. GGGAGGACGAUGCGG GTAATAAACACGACAACGCTTTATTGCCCC CAGACGACUCGCCCGA
Fig. 4. Internalization of individual aptamers into cells. (A) The individual aptamers were incubated with the 16E6/E7 HTECs to allow for binding and internalization,
followed by stringent washing, isolation of RNA, and quantiﬁcation as described in the section “Materials and methods”. The quantity is displayed as the ratio of the aptamers
(Sel2) over an internal spiked control (added after Trizol extraction) called Sel1 all normalized to GAPDH (measured from a separated non-RNAse treated fraction) and
compared to internalization of a negative control aptamer (*po0.05; **po0.01, Student's t-test). (B) Internalization of individual aptamers into 16E6/E7 HTECs (E6/E7) as
compared to internalization into primary HTECs (HTEC). Experiments and quantiﬁcation were performed as in (A) (*po0.05;**po0.01, Student's t-test comparing
internalization into E6E7 with internalization into HTEC).
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malignancies and could be used in combination with chemother-
apeutic agents for treatment of HPV-positive cancers. In the case of
HPV transformation, aptamer internalization would not necessa-
rily have to be cell-speciﬁc since siRNA against HPV genes would
be speciﬁc for HPV-transformed cells. Another possible use of cell-
internalizing aptamers would be to use them to carry in aptamers
that target the E6 and/or E7 proteins speciﬁcally. Interestingly,
RNA aptamers that associate with 16E7 have been identiﬁed
(Nicol et al., 2013; Toscano-Garibay et al., 2011). Theoretically,
the internalizing aptamer and the E7 aptamer could be linked to
create a chimera that could both internalize and inhibit E7.
In summary, the cell-SELEX strategy we utilized allowed us to
identify aptamers that internalize into HPV transformed tonsillar
epithelial cells. These aptamers may be of use for delivery of HPV-
speciﬁc therapeutics to HPV-transformed head and neck epithelial
cells. Further studies will be necessary to increase speciﬁcity and
to characterize the mechanism of entry. In addition, it will be
important to test the identiﬁed aptamers for the ability to inter-
nalize into HPV-positive cancer cell lines.
Materials and methods
Cell lines
Primary human tonsillar epithelial cells (HTECs) were isolated
from discarded tonsillar tissue obtained from the University of
Iowa Tissue Procurement Facility under IRB approval using
methods that have been previously described (Hoover et al.,
2007). After establishment, cells were grown in KSFM (Invitrogen)
and passaged using 1:4 as described (Darbro et al., 2005). HTECs
were transduced at early passage with a replication defective
retrovirus 16E6/E7-LXSN expressing HPV-16 E6/E7 and a neomy-
cin resistance marker and selected in G418 as described (James
et al., 2006). 16E6/E7 cells were used at early to mid-passage (P11–
P17) for all experiments.
Cell-SELEX
Generation of aptamers and cell-SELEX was performed accord-
ing to methods described previously (Cerchia et al., 2009b; Thiel
et al., 2012a). DNA oligonucleotides were obtained from Integrated
DNA Technology (IDT, Coralville, IA) that contained the following
sequence: 5′-TCGGGCGAGTCGTCTG-N30-CCGCATCGTCCTCCC-3′.
This generation of aptamers is referred to as Sel2 (Thiel et al.,
2012a). PCR primers for ampliﬁcation and addition of a T7
polymerase site were as follows: 5′primer-TAATACGACTCACTA-
TAGGGAGGACGATGCGG; 3′primer-TCGGGCGAGTCGTCTG. The RNA
aptamer library was generated using a mutant Y639F T7 poly-
merase (Huang et al., 1997) with 2′-ﬂuoro modiﬁed CTP and UTP
(TriLink Biotechnologies) to make the aptamers nuclease-resistant.
The aptamers were puriﬁed by running on denaturing 10%
acrylamide gels. Bands were visualized by UV shadowing, excised,
and eluted with Tris-EDTA followed by ﬁltering with a Centrex
spin ﬁlter and concentrating with an Amicon Ultracel as described.
Aptamers were folded in the presences of tRNA and calcium by
heating to 95 1C for 5 min followed by incubation by incubation at
37 1C for 20 min. The puriﬁed and folded aptamers were then used
in a series of pre-clearing and internalization steps followed by
reverse transcription and PCR to isolate those aptamers that
internalized differentially into 16E6/E7-HTECs as compared to
primary HTECs. In each round of cell-internalization SELEX, RNA
aptamer pools were ﬁrst folded in the presence of calcium in
serum-free KSFM and supplemented with yeast tRNA (Invitrogen)
Fig. 5. Internalization of ﬂuorescently tagged C5 aptamer into 16E6/E7 transformed
cells. The aptamer was labeled with Cy3 and puriﬁed and incubated with cells as
described in the section “Materials and methods”. After washing and trypsinization
the cells were analyzed by FACS. The quantity shown represents the percentage
shift in the number of cells as compared to background autoﬂuorescence. (A)
Internalization into 16E6/E7-HTEC or primary HTEC. (B). Internalization into 16E6/
E7 human cervical epithelial (E6/E7 HCE) or primary cervical epithelial (HCE) cells.
Fig. 6. Localization of C5 aptamer and inhibition of internalization by cold. Cy3
labeled C5 aptamer was incubated with E6/E7-HTECs as described in the section
“Materials and methods” at either 37 1C or 4 1C. The cells were visualized using
ﬂuorescence microscopy as described in the section “Materials and methods”.
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and then pre-cleared with primary HTECs (at passage 3–5) that
had been pre-incubated with tRNA as a pre-clearing step for
20 min at 37 1C. After pre-clearing, the supernatant was trans-
ferred to 16E6/E7-HTECs (always at passage 16) and incubated for
varying lengths of time to allow internalization starting with
75 min in the ﬁrst rounds and decreasing to 20 min in later rounds
to increase stringency. After incubation, to remove unbound and
surface-bound aptamers, the target 16E6/E7 cells were washed
with ice-cold PBS, followed by two high salt washes (0.5 M NaCl),
ﬁrst quickly and then for 5 min, followed by another PBS wash (all
on ice). Internalized RNA aptamers were then recovered using
TRIzol reagent (Invitrogen) following the manufacturer's instruc-
tions. The RNA was reverse transcribed into DNA using SuperScript
III (Invitrogen) and ampliﬁed by PCR using AmpliTaq and Sel2
primers (as above) to amplify and add back the T7 polymerase
promoter. The PCR products were puriﬁed using a Qiagen Mini-
prep Column and then in vitro transcribed to generate an enriched
pool of RNA aptamers for subsequent rounds of cell-SELEX. PCR
samples were also removed from each round for later sequencing.
A total of 12 pre-clearing and selection rounds were performed.
Sequencing and structure analysis
Pools of aptamers were sequenced using 454-deep sequencing
(University of Iowa DNA Facility), processed, and analyzed as
described (Thiel et al., 2012a, 2012b). A script was written using
the Perl programming language to identify unique sequences and
count the number of times each sequence appeared in the dataset.
The percent enrichment was calculated as %Enrichment¼1
(Unique/Total)100 as described previously (Thiel et al., 2012b,
2011). All unique sequences were aligned using ClustalX2 (Larkin
et al., 2007). If clear families of related sequences were present, the
sequence that was represented most in the family was chosen for
follow-up studies. Theoretical structures of RNA were evaluated
using M-fold (Zuker, 2003). The structure with the minimum free
energy was determined for aptamers that increased in number
with more selection.
Internalization assays
RT-qPCR
To assess internalization, primary HTECs (passage 3–5), 16E6/
E7-HTECs (passage 15–17), or ﬁbroblasts (passage 8) were plated
in 6-well dishes at 2105 per well. Internalization was performed
and assessed as described previously (Thiel et al., 2012a). Brieﬂy,
24 h after plating, the cells were washed and incubated ﬁrst with
tRNA followed by incubation with 100 nM folded aptamer in tRNA
mix (see above). The folded aptamer was incubated for 20 min at
37 1C followed by washes in ice-cold PBS followed by high salt
wash (0.5 M). After washing, RNA was collected and processed as
above with the addition that the Trizol samples were spiked with
an internal 2′-ﬂuoropyrmidine aptamer control called Sel1. Sel1
refers to a generation of aptamers that utilizes a different set of
primers than Sel2 for ampliﬁcation (McNamara et al., 2008). In our
assays, we utilized a Sel1 spike aptamer called M12-23 (McNamara
et al., 2008). The Sel1 allows for rigid control of cDNA synthesis,
pipetting, and PCR ampliﬁcation during the puriﬁcation and
quantitation process. Puriﬁed RNA was split into two aliquots.
One was treated with RNase to remove cellular RNA (Aptamer RNA
is resistant to RNase). The other was used for quantiﬁcation of
GAPDH (as another control for cell number). Samples were reverse
transcribed as above and aptamer amount (as well as GAPDH for
the sample that was not treated with RNase) was assessed by
quantitative PCR using appropriate primers as described (Thiel
et al., 2012a). Results are expressed as a Sel2/Sel1 ratio, normalized
to GAPDH levels (obtained from untreated samples). For
experiments with individual aptamers, we also normalized to a
negative control aptamer that had the same constant regions as
the tested aptamers. The negative control that we chose to use was
an aptamer that was present in the original aptamer library but
was not found after later rounds of cell-SELEX.
Fluorescent-labeled aptamers
For the experiments to assess internalization by FACS, cells
were incubated with the folded labeled aptamer in the presence of
tRNA for 45 minutes at 37 1C then washed with high-salt as above,
trypsinized, and stained with Hoechst (to differentiate live and
dead cells). Cells were then analyzed by FACS for Cy3 and Hoechst
uptake using a FACSDiva at the University of Iowa Flow Cytometry
Facility. The percent shift represents the number of cells that are
positive for Cy3 (i.e. aptamer positive) as compared to background
levels.
For the assays to assess internalization at different tempera-
tures, the ﬂuorescently labeled aptamers were folded and incu-
bated in the presence of tRNA with cells grown on coverslips.
During the 90 min incubation, the cells were either kept at 37 1C in
the incubator or on ice. After incubation, the cells were washed
with cold PBS and high-salt as above before microscopic analysis
using a 40 oil immersion objective on an Olympus 1X71
inverted microscope with a cooled charge-coupled device camera
and ﬁlters for Texas Red. Intracellular localization was conﬁrmed
with nuclear DAPI stain and overlapping with Image J software.
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